These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1441 related items for PubMed ID: 17914554

  • 1. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 2. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [Abstract] [Full Text] [Related]

  • 3. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A, Jovanovic D, Jelic S.
    J BUON; 2009 Aug; 14(4):635-9. PubMed ID: 20148455
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY, Xi MR, Yang KX, Yu H.
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [Abstract] [Full Text] [Related]

  • 5. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K.
    Anticancer Res; 2007 Apr; 27(4A):2027-33. PubMed ID: 17649817
    [Abstract] [Full Text] [Related]

  • 6. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 7. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H.
    Gynecol Oncol; 2009 Mar 01; 112(3):537-42. PubMed ID: 19108875
    [Abstract] [Full Text] [Related]

  • 8. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
    Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS.
    Exp Oncol; 2009 Mar 01; 31(1):48-51. PubMed ID: 19300417
    [Abstract] [Full Text] [Related]

  • 9. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM.
    Int J Gynecol Pathol; 2007 Oct 01; 26(4):404-9. PubMed ID: 17885490
    [Abstract] [Full Text] [Related]

  • 10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 11. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Mar 01; 104(3):508-15. PubMed ID: 17113137
    [Abstract] [Full Text] [Related]

  • 12. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 13. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP, Wiemann MC, Miller GA, Geisler HE.
    Gynecol Oncol; 1996 Mar 01; 60(3):424-7. PubMed ID: 8774651
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
    Acs G, Xu X, Chu C, Acs P, Verma A.
    Cancer; 2004 Jun 01; 100(11):2376-86. PubMed ID: 15160341
    [Abstract] [Full Text] [Related]

  • 15. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP.
    Clin Cancer Res; 2006 Mar 01; 12(5):1487-93. PubMed ID: 16533772
    [Abstract] [Full Text] [Related]

  • 16. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Høgdall CK.
    Cancer; 2004 Jun 01; 100(11):2387-95. PubMed ID: 15160342
    [Abstract] [Full Text] [Related]

  • 17. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
    Lee P, Rosen DG, Zhu C, Silva EG, Liu J.
    Gynecol Oncol; 2005 Mar 01; 96(3):671-7. PubMed ID: 15721410
    [Abstract] [Full Text] [Related]

  • 18. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.
    Lancet Oncol; 2013 Aug 01; 14(9):853-62. PubMed ID: 23845225
    [Abstract] [Full Text] [Related]

  • 19. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
    Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D.
    Cancer Res; 2001 Nov 01; 61(21):7811-8. PubMed ID: 11691797
    [Abstract] [Full Text] [Related]

  • 20. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM.
    Clin Cancer Res; 2003 Nov 01; 9(14):5318-24. PubMed ID: 14614016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.